A retrospective study including 20.1% mCRC patients with ECOG PS ≥ 2, showed that patients with poorer PS and comorbidities were significantly more likely than those with better PS to have their tumors tested for RAS status at diagnosis in an attempt to induce tumor response with anti-EGFR monoclonal antibodies (until 60 days after diagnosis) 9. This evidence concerns the gene EGFR and neoplasm.